Urinary biomarker-guided surveillance versus standard cystoscopic surveillance for non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials
In brief
Urinary biomarkers cut bladder cancer surveillance cystoscopies by 56% to 75%
In two randomized trials involving 606 adults with non-muscle-invasive bladder cancer, biomarker-guided surveillance reduced cystoscopy use by 56% in one trial and 75% in the other. Recurrence and progression outcomes showed no significant differences from standard surveillance, but the trials were small and could not establish non-inferiority; larger, longer studies are needed before this approach can replace cystoscopy.
- Journal
- World journal of urology (Q1)
- Published
- 15 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Faris Abushamma, Hammam Abdalrazeq, Orabi Hajjeh, Sima Algharaba, Hossam Salameh, Leen Jarrad, et al.
- PMID
- 43034244
- DOI
- 10.1007/s00345-026-06926-9
Why clinicians should know about it
- Picked for Urology (paper of the day, 16 November 2026): Randomized evidence on biomarker-guided NMIBC surveillance
- Picked for Surgical Oncology (paper of the day, 16 November 2026): Randomized evidence supports less cystoscopy in bladder surveillance
Abstract
PURPOSE: To compare urinary biomarker-guided surveillance with standard cystoscopy-based surveillance in non-muscle-invasive bladder cancer (NMIBC) with respect to cystoscopy use and oncological outcomes. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials comparing urinary biomarker-guided surveillance with standard cystoscopy-based surveillance in adults with NMIBC. PubMed, Embase, and Scopus were searched from inception through August 2026. Random-effects meta-analyses were used for comparative oncological outcomes, and pooled estimates were considered exploratory. Cystoscopy utilization was summarized descriptively using the total number of cystoscopies performed, cystoscopies per participant, absolute and relative reductions in cystoscopy use, and the number of cystoscopies performed per detected recurrence. RESULTS: Two randomized controlled trials, DaBlaCa-15 and UroFollow, randomized 606 participants, with 590 contributing to the principal comparative analyses. Biomarker-guided surveillance reduced cystoscopy use by 55.8% in DaBlaCa-15 and 74.9% in UroFollow. There was no significant difference in any recurrence (RR 1.04, 95% CI 0.77-1.41), high-grade recurrence or disease progression (RR 1.03, 95% CI 0.61-1.74), or progression to muscle-invasive or metastatic disease (RR 0.57, 95% CI 0.12-2.67). CONCLUSION: In the two available randomized trials, biomarker-guided surveillance substantially reduced cystoscopy use and did not show evidence of worse recurrence or progression outcomes, although non-inferiority could not be established. However, the evidence base is small, the surveillance strategies and risk groups differ, and progression events were uncommon. This review adds randomized evidence that biomarker-guided surveillance can reduce cystoscopy use, but larger trials with longer follow-up are needed before it can replace guideline-based cystoscopy.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.